GH.png

JWCA advises Guardant Health on its $550 million convertible and capped call issuance

November 2026 | read press release

Transaction Background

Guardant Health, Inc. (“Guardant” or the “Company”) raised $550mm convertible debt at attractive terms (0.00% coupon and 35.0% conversion premium), while refinancing ~$395.2mm (80.5%) of the outstanding convertible due 2027

Guardant’s objectives included:

  • Refinance a majority of convertible due in November 2027

  • Protect against future equity dilution through derivative overlay

  • Minimize stock price risk during execution

JWCA provided extensive analysis for Guardant for the transaction, including:

  • Convertible refinancing scenarios

  • Accounting implications

  • Shareholder messaging

  • Convertible and capped call documentation to ensure maximum value and future efficiency/flexibility

The transaction was conducted privately using a wall cross process, before flipping into an overnight marketed transaction

JWCA designed and ran a capped call auction process to achieve competitive terms

JWCA provided advice, support and analysis throughout the execution process

Results

Guardant’s convertible transaction was very well received by investors:

  • The transaction reflected strong investor demand in the Company’s offering from investors

  • The Company was able to achieve a 0.00% fixed coupon and priced at mid point of the wall cross marketed conversion premium range

  • Refinanced ~80.5% of the Company’s 2027 convertible notes

GH eliminated stock price risk, as the transaction was executed via a confidential wall cross process, and priced overnight with convertible investors

Capped call auction process produced considerable savings for Guardant